Drugs / CAL02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05776004 | Jul 2023 → Feb 2026 overdue | bacterial pneumonia | Eagle Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02583373 Comparator | Mar 2016 → Feb 2018 | streptococcal pneumonia | Combioxin SA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAL02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05776004 ↗ |
| Modality | Other / unclassified | “CAL02, a novel antitoxin agent with an unprecedented mode of action, consists of liposomes that capture bacterial toxins” PMID 31056427 ↗ May 2019 |
| Route | Intravenous | “Two intravenous doses of study treatment were infused” PMID 31056427 ↗ May 2019 |